1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment outcomes of patients treated with venetoclax-obinutuzumab therapy vs BTKi therapies in 1L CLL: An international real-world study
    Meeting Abstract

    Lamanna, N.; Brown, J. R.; Ujjani, C. S.; Eyre, T. A.; Manzoor, B.; Ghosh, N.; Roeker, L.; Davids, M. S.; Coombs, C. C.; Skarbnik, A. P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Prediction of clinical response by phased variants in circulating tumor DNA (ctDNA) in the VALENTINE-PTCL01 trial of patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL)
    Meeting Abstract

    Mehta-Shah, N.; Horwitz, S.; Zinzani, P. L.; Barta, S. K.; Yamagishi, M.; Kurtz, D. M.; Takayama, G.; Hizukuri, Y.; Feng, W.; Chang, K. C. N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Molecular features are associated with disease stage in diffuse large B-cell lymphoma and reveal heterogeneity in patient outcomes
    Meeting Abstract

    Uppal, M.; Gurumurthi, A.; Hamlin, P. A.; Falchi, L.; Horwitz, S.; Kumar, A.; Noy, A.; Lue, J. K.; Torka, P.; Arcila, M. E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Outcomes with HMA plus venetoclax vs intensive chemotherapy in AML patients with chromosome 5 and 7 abnormalities
    Meeting Abstract

    Boussi, L.; Bewersdorf, J. P.; Liu, Y.; Shallis, R. M.; Aguirre, L. E.; Zucenka, A.; Garciaz, S.; Bystrom, R. P.; DeAngelo, D. J.; Stone, R. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Outcomes and survival in newly diagnosed, older, acute myeloid leukemia patients from the beat AML master trial in the venetoclax/azacitidine age
    Meeting Abstract

    Borate, U.; Huang, Y.; Li Welkie, R.; Swords, R. T.; Traer, E.; Stein, E. M.; Lin, T. L.; Madanat, Y. F.; Patel, P. A.; Collins, R. H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with lower-intensity therapy
    Meeting Abstract

    Hoff, F. W.; Huang, Y.; Li Welkie, R.; Swords, R. T.; Traer, E.; Stein, E. M.; Lin, T. L.; Patel, P. A.; Collins, R. H.; Baer, M. R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Comparative analysis of outcomes with HMA plus venetoclax vs intensive chemotherapy in AML patients harboring very-high risk cytogenetics
    Meeting Abstract

    Aguirre, L. E.; Bewersdorf, J. P.; Liu, Y.; Shallis, R. M.; Boussi, L.; Zucenka, A.; Garciaz, S.; Bystrom, R. P.; Deangelo, D. J.; Stone, R. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Validation of dynamic deep learning for the prediction of cancer-associated thrombosis
    Meeting Abstract

    Mantha, S.; Singh, R.; Zwicker, J. I.; Li, A.
    Blood (2024)

    Fulltext@MSK | Save
  • Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with relapsed or refractory, splicing factor-mutant myeloid malignancies
    Meeting Abstract

    Bewersdorf, J. P.; Mi, X.; Lu, B.; Kuykendall, A. T.; Sallman, D.; Patel, M.; Stevens, D. A.; Philipovskiy, A.; Sutamtewagul, G.; Masarova, L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Updated comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy using a matching-adjusted indirect comparison
    Meeting Abstract

    Lopez-Muñoz, N.; Bar, N.; Diels, J.; van Sanden, S.; Mendes, J.; Lee, S.; Hernando, T.; Lendvai, N.; Patel, N.; Ishida, T.; more...
    Blood (2024)

    Fulltext@MSK | Save